Figure 1 : GCs specifically repress expression of enzymes required for OCY-mediated perilacunar remodeling.

From: Glucocorticoid suppression of osteocyte perilacunar remodeling is associated with subchondral bone degeneration in osteonecrosis

Figure 1

Bones from 2-month-old male FVB mice treated for 7 or 21 days with placebo or prednisolone were analyzed by μCT. (A) Bone volume over tissue volume (BV/TV) and (B) cortical thickness (Ct. Th.) were measured at the proximal femur and mid-shaft, respectively. (C) Histological sections of femurs stained with hematoxylin and eosin (scale bar = 50 μm) in proximal trabecular bone and mid-shaft cortical bone after 21 days treatment with placebo and prednisolone. Gene expression for GILZ, MMP2, MMP13, MMP14, CatK, TRAP, and CA-2 was evaluated in mRNA from marrow-free humeri extracted from mice after 7 days (D) of treatment with placebo or prednisolone, measured by RT-qPCR. All mRNA levels were normalized to ribosomal protein L19 mRNA levels and placebo treated animal expression. For all analyses, *p-value ≤ 0.05 vs. placebo-treated control, bars represent average ± SEM from n ≥ 6 animals for each group.